CAMs as counter measures against infectious and inflammatory disease

CAM 作为对抗传染病和炎症性疾病的对策

基本信息

  • 批准号:
    7574619
  • 负责人:
  • 金额:
    $ 120万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-09-30 至 2013-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): CAMs are used for the prevention and treatment of infectious and inflammatory diseases, though for many of these CAMs, their true efficacy and the molecular basis for their purported benefits have not been defined and/or confirmed. We propose a new Center of Excellence for Research on CAMs (CERC) focused on the study of the mechanisms of action of diverse CAMs in models of pulmonary and intestinal infectious disease. Since in many instances the resulting inflammatory response associated with infection in the lung and intestinal track accounts for the actual pathology in the disease, we also intend to expand ongoing efforts in using CAMs to minimize inflammation induced tissue damage. The ultimate goal of this CERC is to provide critical insight into the mechanisms of action of select CAMs that can be used as countermeasures against emerging and select agents that infect the pulmonary and intestinal mucosa. This Center brings together scientists with expertise in bacterial and viral diseases of the lung and intestinal tract, study of CAM effects on innate leukocytes and epithelial cells, purification of defined agonists from crude plant extracts, use of probiotic CAMs, and use of rodent models of infectious and inflammatory disease to define specific mechanisms of action. This Center will also take advantage of new BSL-3 facilities to study the impact of CAMs on select agents. The CERC will initially be focused on three distinct projects, which will be supported by two Cores: Administrative (Core A) and Animal Model (Core B). The three Research Projects are: Project 1) CAMs that enhance ??T cell function, Project Leader, Mark Jutila, Ph.D.; Project 2) Anti-viral CAMs, Project Leader, Dr. Michele Hardy, Ph.D.; and Project 3) Anti-inflammatory microbial CAMs and arthritis, Project Leader, Dr. David Pascual, Ph.D. The Animal Models Core will serve as a unique and highly interactive resource, facilitating synergy and collaboration between the three research projects. PUBLIC HEALTH RELEVANCE: CAMs are widely used by the public to treat a variety of ailments, however, in many instances their true efficacy, safety and specific mechanisms of action are unknown. This proposed CERC provides a unique focus on mechanistic studies of CAMs that counter infectious and inflammatory disease. It directly addresses the goals of the NCCAM, and will provide important new information relevant to the use of CAMs.
描述(由申请人提供):CAMs用于预防和治疗感染性和炎症性疾病,尽管对于许多这些CAMs,其真正功效和其声称益处的分子基础尚未确定和/或证实。我们建议建立一个新的CAMs卓越研究中心(CERC),重点研究各种CAMs在肺部和肠道传染病模型中的作用机制。由于在许多情况下,与肺部和肠道感染相关的炎症反应解释了疾病的实际病理,我们也打算扩大正在进行的使用CAMs的努力,以尽量减少炎症诱导的组织损伤。CERC的最终目标是提供对选定CAMs的作用机制的关键见解,这些CAMs可用于对抗感染肺和肠粘膜的新兴和选定病原体。该中心汇集了具有肺和肠道细菌和病毒疾病专业知识的科学家,研究CAM对先天白细胞和上皮细胞的影响,从粗植物提取物中纯化确定的激动剂,益生菌CAM的使用,以及使用传染病和炎症疾病的啮齿动物模型来确定具体的作用机制。该中心还将利用新的BSL-3设施来研究cam对选定药剂的影响。CERC最初将侧重于三个不同的项目,这些项目将由两个核心提供支持:行政(核心A)和动物模型(核心B)。这三个研究项目是:项目1)增强??T细胞功能,项目负责人,Mark Jutila博士;项目2)抗病毒cam,项目负责人Michele Hardy博士;抗炎微生物CAMs和关节炎,项目负责人,Dr. David Pascual博士。动物模型核心将作为一个独特的、高度互动的资源,促进三个研究项目之间的协同和合作。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Mark A Jutila其他文献

Mark A Jutila的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Mark A Jutila', 18)}}的其他基金

Development of novel, safe and efficacious Coxiella burnetii vaccine
新型、安全、有效的伯氏柯克斯体疫苗的研制
  • 批准号:
    8952597
  • 财政年份:
    2015
  • 资助金额:
    $ 120万
  • 项目类别:
Role of type I IFN and human TLR4 in Coxiella burnetii pathogenesis
I 型 IFN 和人 TLR4 在伯氏柯克斯体发病机制中的作用
  • 批准号:
    9195688
  • 财政年份:
    2015
  • 资助金额:
    $ 120万
  • 项目类别:
Role of Toll-like receptors in Coxiella burnetii infection
Toll样受体在伯氏柯克斯体感染中的作用
  • 批准号:
    8302673
  • 财政年份:
    2012
  • 资助金额:
    $ 120万
  • 项目类别:
Role of Toll-like receptors in Coxiella burnetii infection
Toll样受体在伯氏柯克斯体感染中的作用
  • 批准号:
    8546297
  • 财政年份:
    2012
  • 资助金额:
    $ 120万
  • 项目类别:
MT VET COBRE II CORE B: CELLULAR ANALYSIS CORE
MT VET COBRE II 核心 B:细胞分析核心
  • 批准号:
    8360159
  • 财政年份:
    2011
  • 资助金额:
    $ 120万
  • 项目类别:
MT VET COBRE II CORE B: CELLULAR ANALYSIS CORE
MT VET COBRE II 核心 B:细胞分析核心
  • 批准号:
    8168413
  • 财政年份:
    2010
  • 资助金额:
    $ 120万
  • 项目类别:
MT VET COBRE CORE C: CELL ANALYSIS CORE
MT VET COBRE 核心 C:细胞分析核心
  • 批准号:
    7960523
  • 财政年份:
    2009
  • 资助金额:
    $ 120万
  • 项目类别:
Enhancement of Innate Immunity Against Coxiella Pneumonia
增强针对柯克斯体肺炎的先天免疫
  • 批准号:
    7675558
  • 财政年份:
    2009
  • 资助金额:
    $ 120万
  • 项目类别:
MT VET COBRE CORE C: CELL ANALYSIS CORE
MT VET COBRE 核心 C:细胞分析核心
  • 批准号:
    7721023
  • 财政年份:
    2008
  • 资助金额:
    $ 120万
  • 项目类别:
CAMs as counter measures against infectious and inflammatory disease
CAM 作为对抗传染病和炎症性疾病的对策
  • 批准号:
    8302174
  • 财政年份:
    2008
  • 资助金额:
    $ 120万
  • 项目类别:

相似海外基金

Wearable Microsystem for Continuous Personalized Aerosol Exposure Assessment
用于连续个性化气溶胶暴露评估的可穿戴微系统
  • 批准号:
    10747130
  • 财政年份:
    2023
  • 资助金额:
    $ 120万
  • 项目类别:
Counter Bias Training Simulation (CBTsim) Healthcare: A Novel Approach for Reducing the Impact of Implicit Bias on Healthcare Delivery
反偏见培训模拟 (CBTsim) 医疗保健:减少隐性偏见对医疗保健服务影响的新方法
  • 批准号:
    10637978
  • 财政年份:
    2023
  • 资助金额:
    $ 120万
  • 项目类别:
Over-The-Counter Hearing Aid Treatment For Adults With Cognitive Decline Due To Alzheimer's Disease And Related Dementias
针对因阿尔茨海默病和相关痴呆症而导致认知能力下降的成年人的非处方助听器治疗
  • 批准号:
    10740008
  • 财政年份:
    2023
  • 资助金额:
    $ 120万
  • 项目类别:
Decoding natural protective mechanisms during diapause and longevity to counter aging
解码滞育和长寿期间的自然保护机制以对抗衰老
  • 批准号:
    10687588
  • 财政年份:
    2023
  • 资助金额:
    $ 120万
  • 项目类别:
Community Partnership for Telehealth Solutions to Counter Misinformation and Achieve Equity (PRIME)
反虚假信息和实现公平的远程医疗解决方案社区合作伙伴关系 (PRIME)
  • 批准号:
    10608871
  • 财政年份:
    2022
  • 资助金额:
    $ 120万
  • 项目类别:
Targeting alpha-cell GPCRs to stimulate glucagon and counter hypoglycemia
靶向 α 细胞 GPCR 刺激胰高血糖素并对抗低血糖
  • 批准号:
    10427574
  • 财政年份:
    2022
  • 资助金额:
    $ 120万
  • 项目类别:
Community Partnership for Telehealth Solutions to Counter Misinformation and Achieve Equity (PRIME)
反虚假信息和实现公平的远程医疗解决方案社区合作伙伴关系 (PRIME)
  • 批准号:
    10706426
  • 财政年份:
    2022
  • 资助金额:
    $ 120万
  • 项目类别:
Integration of new analysis method to predict scattering and diffusion of volcanic ejecta into counter measures for prevention against disaster
将预测火山喷发物散射和扩散的新分析方法纳入防灾对策
  • 批准号:
    22H00248
  • 财政年份:
    2022
  • 资助金额:
    $ 120万
  • 项目类别:
    Grant-in-Aid for Scientific Research (A)
Nanomaterial Radioisotope Detectors for Intracellular Measurements
用于细胞内测量的纳米材料放射性同位素探测器
  • 批准号:
    10482292
  • 财政年份:
    2022
  • 资助金额:
    $ 120万
  • 项目类别:
Targeting alpha-cell GPCRs to stimulate glucagon and counter hypoglycemia
靶向 α 细胞 GPCR 刺激胰高血糖素并对抗低血糖
  • 批准号:
    10675646
  • 财政年份:
    2022
  • 资助金额:
    $ 120万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了